{"denoms":[{"counts":[{"groupId":"BG000","value":"593"},{"groupId":"BG001","value":"590"},{"groupId":"BG002","value":"1183"}],"units":"Participants"}],"groups":[{"description":"Participants were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.","id":"BG000","title":"FOLFOX + Panitumumab"},{"description":"Participants were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.","id":"BG001","title":"FOLFOX Alone"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.1","value":"61.5"},{"groupId":"BG001","spread":"11.0","value":"60.3"},{"groupId":"BG002","spread":"10.6","value":"60.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"207"},{"groupId":"BG001","value":"232"},{"groupId":"BG002","value":"439"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"386"},{"groupId":"BG001","value":"358"},{"groupId":"BG002","value":"744"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"530"},{"groupId":"BG001","value":"540"},{"groupId":"BG002","value":"1070"}]}],"title":"White or Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"23"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"68"}]}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"12"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"10"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"332"},{"groupId":"BG001","value":"329"},{"groupId":"BG002","value":"661"}]}],"title":"Western Europe, Canada and Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"261"},{"groupId":"BG001","value":"261"},{"groupId":"BG002","value":"522"}]}],"title":"Rest of world"}],"description":"Stratification factor. Rest of world includes South America, eastern Europe, South Africa and Mexico","paramType":"NUMBER","title":"Geographic Region","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"325"},{"groupId":"BG001","value":"331"},{"groupId":"BG002","value":"656"}]}],"title":"Wild-type KRAS"},{"categories":[{"measurements":[{"groupId":"BG000","value":"221"},{"groupId":"BG001","value":"219"},{"groupId":"BG002","value":"440"}]}],"title":"Mutant KRAS"},{"categories":[{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"87"}]}],"title":"Unevaluable KRAS"}],"description":"KRAS, the human homolog of the Kirsten rat sarcoma-2 virus oncogene","paramType":"NUMBER","title":"KRAS Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"332"},{"groupId":"BG001","value":"320"},{"groupId":"BG002","value":"652"}]}],"title":"Grade 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"230"},{"groupId":"BG001","value":"238"},{"groupId":"BG002","value":"468"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"60"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"Grade 4"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}],"title":"Mising/Unknown"}],"description":"Grade 0: Fully active, able to carry on all pre-disease performance without restriction; Grade 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; Grade 2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about \\> 50% of waking hours; Grade 3: Capable of only limited self care, confined to a bed or chair \\> 50% of waking hours; Grade 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; Grade 5: Dead","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"394"},{"groupId":"BG001","value":"398"},{"groupId":"BG002","value":"792"}]}],"title":"Colon cancer"},{"categories":[{"measurements":[{"groupId":"BG000","value":"199"},{"groupId":"BG001","value":"192"},{"groupId":"BG002","value":"391"}]}],"title":"Rectal cancer"}],"paramType":"NUMBER","title":"Primary tumor type","unitOfMeasure":"participants"}]}